Press "Enter" to skip to content

Mexico will participate in phase 3 trial of the vaccine developed by Novavax, reveals Ebrard

The Mexican Chancellor, Marcelo Ebrard, announced that the biotechnology company Novavax, Inc start your phase 3 study of the vaccine against COVID-19 in Mexico and United States, so it will recruit up to 30 thousand volunteers in these nations.

In order to evaluate the effectiveness of the vaccine NVC-CoV2373, In the Mexican Republic, the company seeks to recruit 2,000 volunteers in 7 locations in the country, “which will allow us to collect data on the efficacy of the vaccine in our population.”

“The clinical trials Previous studies showed that the vaccine elicited a robust immune response against the virus and was well tolerated. The new Novavax study plans to recruit volunteers who belong to the demographic groups that have been most affected by the virus. SARS-CoV-2, as well as the elderly or those with comorbidities ”, the company explained.

Likewise, Novavax, Inc thanked the collaboration and participation of Government of Mexico in this study, which will begin once the Federal Commission for the Protection against Sanitary Risks (Cofepris) grants its approval.

It is worth mentioning that the NVX-CoV2373 vaccine has been developed with the support of the United States Government, which expressed its support for the Government of Mexico in accessing the vaccines developed in its country in the framework of the visit of President Andrés Manuel López Obrador to Washington DC, on July 8, 2020.

It may interest you: Presents “unexplained neurological disorder” second volunteer for the covid-19 vaccine from AstraZeneca

Sputnik V to Mexico! Russia offers 2,000 doses of COVID-19 vaccine for clinical trials

IPN seeks 80 volunteers for COVID-19 vaccine study; these are the requirements

The first vaccines against COVID-19 arrive in Coahuila; today the vaccination campaign begins

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *